News

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Pre-Market Stock Futures: Futures are trading mixed after a second brutal day, with all major indices finishing lower again. Rising rates, Brent Crude trading above $100, and what appears to be an increase in the Iran attacks in the Persian Gulf were all it took for sellers to keep hitting bids. Once again, the small-cap […]

Here are four highlights of a rocky day in markets Tuesday. Canadian tariffs on U.S. goods kicked in. Oil rose, while stocks fell. Amgen stock shed 10% Howmet Aerospace was the worst performer in the S&P.

📣 “This is the worst possible outcome for Amgen.” —Barclays analyst Emily Field, on Novartis announcing a disappointing result for its heart disease drug, a disclsoure that also cast doubt on one of Amgen's big drugs.

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.

Major stock indexes faced pressure on Tuesday with a fresh slate of geopolitical tensions weighing on investors. The Dow industrials are down about 1%. Meanwhile, quantum computing stocks are on the rise.

AI stocks rise despite the market’s inflation worries, but Amgen falls following Swiss drugmaker Novartis’ disappointing trial data.

U.S. markets wobbled as higher oil prices dragged sentiment before investors return from the Labor Day weekend.

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

President Trump is asking cybersecurity and tech companies to take on a potentially dangerous new role attacking foreign cybercriminals, but the plan offers few incentives to balance the risks. Genetic testing lab Baylor Genetics disclosed a cyber incident where a hacker had access to certain internal systems between June 11 and June 17. An unspecified number of patients had their medical testing and lab results compromised while current and former employees had their Social Security numbers and financial account data exposed, Baylor said.

Revenue surged 10% as six growth drivers now fuel 70% of product sales.

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures (ESU26 ) are up +0.33%, and September E-mini Nasdaq futures...

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Wall Street futures pointed moderately higher pre-bell Tuesday after software giant Palantir Technol

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Amgen trades at $365.22 per share and has stayed right on track with the overall market, gaining 12% over the last six months. At the same time, the S&P 500 has returned 7.7%.

July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move ‌by a U. In granting a preliminary injunction, Chief Judge Daniel Domenico ‌of the Denver federal court said Amgen would likely face significant and irreparable harm from charging lower prices, ​adding that it could affect the drugmaker's negotiations for future contracts with wholesalers and distributors.

The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.

This new ranking also showcases tech giants Alphabet, Microsoft, Meta and Cisco, propelled by high scores for innovation, financial strength and AI readiness

The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.

Quantinuum’s IPO grabbed headlines, but its first trading day showed both excitement and caution. How can investors approach QNT stock after its Wall Street debut?